Vaxart, Inc. (VXRT) Earnings Call Transcript & Summary

August 8, 2024

OTC Pink Market US Health Care Biotechnology earnings 27 min

Earnings Call Speaker Segments

Steven Lo

executive
#1

Thank you, Ed, and I appreciate everyone being on this call this afternoon. I'm eager today to walk through what we've recently achieved across both our COVID and norovirus efforts, as well as lay out the milestones ahead. After that, I'll hand things over to James, who will go deeper on our planned BARDA-funded phase 2b COVID trial and our discussions with FDA regarding norovirus. Then Phil will provide the financial update, and following that we'll take your questions. Since coming to Vaxart in March, I've been able to engage with every function across the company, and I can say with certainty that there's a profound dedication to pushing our science forward and to driving execution throughout the whole organization — something that has been a strategic priority for us, especially considering what a biotech developing breakthrough technology typically faces. That same technology is what drew me to Vaxart. I have faith in the transformative promise of our oral pill vaccine platform. Five months into my role as CEO, I hold strong confidence in our team, who are working diligently toward delivering solutions for some of the most serious infectious disease threats facing society. Halfway through 2024, I'm pleased to report that we've hit the targets we set for ourselves at the mid-year mark. Starting with COVID: in June we told you we were thrilled to land one of the largest BARDA awards granted to date through Project NextGen. That contract, valued at up to $453 million, was issued under Project NextGen — a $5 billion initiative from the Department of Health and Human Services focused on developing new vaccines and treatments capable of providing wider and more durable protection against COVID-19. This recognition highlights the potential of our platform. It also emphasizes both the chance we have to rethink how vaccines get made and delivered around the world, and how urgent our mission is. As James will explain soon, our dialog with FDA remains active and productive, and once they align with us, we'll launch this phase 2b trial. Now to norovirus. We've made significant strides during the last 12 months and stand ready to advance this program further. In late April, we reported positive top line data from our Phase 1 clinical trial in lactating mothers, which may help us reach our long-term aim of shielding infants via passive antibody transfer. As a reminder, the Bill and Melinda Gates Foundation partially funded this trial. In addition to that strong recent information, we previously reported positive phase two findings from the norovirus challenge study we conducted. Norovirus remains an essential component of both our pipeline and our broader strategy, and our confidence is unchanged that this program will yield favorable outcomes that benefit health worldwide. It transmits readily and is the leading source of acute gastroenteritis symptoms, which include vomiting and diarrhea. About 21 million people in the United States become sick with it every year, and within that number are 15% of children under five who contract norovirus each year. Because no norovirus vaccine has received approval, parents will continue to miss work in order to care for kids who are ill with this disease. Beyond that, according to figures from the NIH, people aged 65 and up run a significant danger of serious illness and clinical results, encompassing extended periods of sickness as well as fatalities. Within the US alone, norovirus imposes an annual economic toll from disease amounting to $10.6 billion. At present, we maintain ongoing communication with the FDA, which includes providing further details they've asked for; we're eager to continue our productive talks, as these will help shape both the regulatory route and the upcoming clinical stages for this initiative. Let me take a moment to discuss where we stand financially as a biotech that's still in the clinical stage. Bringing a truly innovative new vaccine all the way to market takes a lot of money, and pushing our runway out into 2026 strengthened our capital base. That gives us room to put funds into innovation and continue moving forward on our company objectives as leaders in oral vaccines. Our distinct strategy, centered on mucosal immunity, is something we see as central to winning. A mucosal vaccine capable of cross-reacting with multiple strains could do more to stop transmission than the shots we have today, particularly when viruses keep mutating. From a public health standpoint, that's an essential need for protecting people against infectious diseases. While the evidence base continues to develop, our dedication to moving these initiatives forward hasn't wavered. We're eager to keep everyone informed about the conversations we're having with the FDA, to bring you news from our Phase 2b COVID study that BARDA is funding, and to lay out what comes next for our norovirus effort. At this point I'll hand things over to James, who will walk through more detail on how our COVID-19 and norovirus programs have progressed lately.

James Cummings

executive
#2

Thanks, Steve. I share Steve's sentiment, and we're grateful for the money BARDA has given Vaxart so we can assess our oral pill, XBB, our COVID-19 vaccine candidate, in a Phase 2b clinical trial. In our view, this support matters for two main reasons. First, it lets us further confirm both our platform and our program through a sizable clinical trial that goes up against an mRNA comparator, and second, it shows considerable interest on the part of the U.S. government, since BARDA sees the need for a next generation COVID vaccine. We're thrilled to have gained their backing. We've continued to build up a strong set of evidence regarding our COVID vaccine candidate, and our expectation is that this study will demonstrate that the candidate enhances immune responses at mucosal surfaces — those linings found within the nose, the mouth, along the eyes, and at other sites in the body where absorption occurs, which are particularly vulnerable to infection. Given the cross reactivity our vaccine candidates exhibit, we think mucosal immune responses could have a meaningful impact against variants as they emerge, while offering better safety and tolerability than the mRNA comparator. I'll now walk through the specifics of how our trial is designed and where we currently stand as this study gets underway. This Phase 2b study is a randomized, controlled, comparator trial that is double blind and conducted across multiple centers. Its goal is to determine how well Vaxart's oral COVID-19 pill vaccine performs relative to an approved mRNA shot for COVID-19 in terms of efficacy, safety, and immunogenicity, in adults who have already been immunized against the virus. Under the planned design, about 10,000 healthy adults aged 18 and up in the United States would be enrolled — 5000 receiving Vaxart's COVID-19 vaccine candidate and another 5000 receiving an approved mRNA product. For the comparator, at least 25% of subjects, based on baseline characteristics, should be at high risk for disease, and we anticipate that every subject has previously received an mRNA injection and likely some have had COVID infection. This trial is going to measure how well the vaccine works against both symptomatic and asymptomatic illness. It's also going to assess immune responses in the blood and at mucosal sites, along with how often any side effects occur. When it comes to the main goal, that's the relative efficacy of Vaxart's COVID-19 vaccine candidate versus an approved mRNA shot, looking at prevention of symptomatic disease. The primary efficacy readout happens once every participant has either dropped out or finished the study visit scheduled for twelve months after vaccination. Enrollment should wrap up in roughly half a year, based on our expectations. There may also be an interim look at vaccine efficacy once 255 clinical COVID-19 cases have accumulated. As far as the designed endpoints go, we'll be checking for cross reactivity, which includes responses in blood, saliva and nasal samples. The study is also going to look at safety, tolerability, and immunogenicity, with particular attention paid to systemic and mucosal responses. Participants are going to record information in electronic diaries and provide swabs on a weekly basis. With data like these, it becomes possible to analyze things quickly even though this study is quite large, and an Independent Data and Safety Monitoring Board, or DSMB, is going to go over the safety data for every person enrolled. Trial preparations, the overhead associated with working with the CROs, and other expenses connected to the trial are all covered by Project NextGen's funding. We meet with BARDA often so that everyone remains aligned regarding how the trial will be carried out. Right now, we're aiming to kick off the Phase 2b clinical trial potentially in the latter portion of 2024, though that depends on getting on the same page as the FDA. So far, we've responded to a lot of questions from the FDA, and we're still in talks with their regulatory group. Getting through this takes time, no doubt, but before we can begin the study, we have to be sure we're aligned with the FDA. As we shared before, our manufacturing processes were ready before the trial was set to launch, and our current projection is that the first patient will be dosed during the second half of 2024. Next, I'd like to share where things stand with the FDA regarding our norovirus program. The FDA gave us useful input on our data related to possible correlative protection, and on what lies ahead for our norovirus program. That conversation with the agency also covered the clinical results we have generated so far, including the dose ranging Phase 2b trial of our bivalent norovirus vaccine candidate and the Phase 2 challenge study of the G11 component of that bivalent norovirus vaccine. At this point, the FDA has requested more information, and that will prompt additional dialogue and feedback. We are working on submitting that information right now, and what happens after that will be settled once our talks with the FDA wrap up. Phil Lee, our Chief Financial Officer, is up next to walk through the numbers briefly. Phil, over to you.

Phil Lee

executive
#3

James, thank you. Today's press release contains a summary of the specifics of our financial results for the second quarter of 2024. For the second quarter of 2024, revenue came in at $6.4 million, versus $1.4 million during the second quarter of 2023. The revenue in the second quarter of 2024 came mainly from revenue recognized or work performed under Vaxart's contract with BARDA awarded in January 2024. The revenue in the second quarter of 2023 came mainly from revenue recognized or work performed under Vaxart's grant from the Bill and Melinda Gates Foundation. Vaxart closed the second quarter of 2024 with cash, cash equivalents and investments of $62.6 million. After the quarter closed, we got a payment of roughly $64.7 million from BARDA. Proceeds from the $64.7 million payment. It will be used to continue study startup activities for the COVID-19, Phase 2b clinical trial, based on our current plan, Vaxart continues to anticipate cash runway into 2026. Thanks everyone for your time today. We will now open the call for your questions.

Elaine Kim

analyst
#4

Hello, this is Elaine Kim, filling in for Charles. We appreciate you taking our questions. Regarding the Norovirus program, could you give us more detail on the extra information the FDA asked for, and how do you expect the phase 2b trial design to differ from the earlier phase 2 studies you ran?

Steven Lo

executive
#5

Hello, Elaine, thank you for asking. I'll hand that over to James, because he was the one who gave some of those comments.

James Cummings

executive
#6

Appreciate it, Steve. As you would anticipate, the FDA is going through the pre-clinical and clinical data we have on norovirus. Right now, we aren't giving out specifics about what those FDA conversations involve. That's still in progress, and it matches how most companies handle things, I believe — they don't reveal particular details while talks with the agency are active, or when we can tell you about what comes next for the norovirus program. Once those talks wrap up, we will definitely share that; and regarding what you asked, I think the second part of it was how the phase 2b trial would be affected, and that, once again, hinges on the specifics of those discussions. Thank you.

Ed Berg

executive
#7

Thanks. Questions have come in from our end. The initial one is this: for kicking off the phase 2b COVID trial, which steps are still left to take? And tied to that, what further details does the FDA require prior to securing their go-ahead for launching that trial? I believe Dr. Cummings is the one to handle this,

James Cummings

executive
#8

Thanks. As you're aware, our conversations with the FDA are still going on and remain quite productive. A number of the comments they raised have already been taken care of, and we expect to close out the rest of them before long. That said, as I mentioned earlier, we're like most companies in that we won't go into detail about what those continuing discussions involve. Ahead of kicking off this trial, our manufacturing process preparations are now largely finished, and we've produced enough vaccine supply to move ahead. Among the other important startup activities for the trial are activating trial sites and subcontracting with a range of vendors. When there's something warranted to share, we intend to give an update. Thanks.

Ed Berg

executive
#9

Thank you. I have another follow-up regarding the phase 2b COVID trial we're running for Dr. Cummings. After that phase 2b COVID study gets underway, could you walk through how subjects get enrolled? And what difficulties could come up when it comes to bringing in 10,000 adults for that research?

James Cummings

executive
#10

Thank you. Look, when we look at this, we see it as a real chance for the clinical trial management group we have, which is highly seasoned, to show what we can do when it comes to recruiting and getting 10,000 subjects signed up for this study. Our expectation was that the demographics in this study would mirror the population of the United States, and that 25% of those taking part would be viewed as being at high risk for severe COVID-19 disease. A number of those factors would include things such as diabetes, coronary artery disease, asthma, obesity with a BMI of greater than 30, increased age, and chronic kidney or lung diseases.

Edward Berg

analyst
#11

Appreciate it. Our following question returns to the COVID trial along with the contract — specifically the agreement involving ATI. Phil, could you explain what that $64.7 million payment covered, and which milestones must be met for the COVID phase 2b study so that we can secure the extra funds from BARDA by way of ATI?

Phil Lee

executive
#12

That $64.7 million we got came from the fact that we'd already hit one milestone under that ATI contract. What you're talking about is the contract worth up to $450 million, $3 million, since we signed an agreement with the CRO — the rest of the money in that contract isn't actually linked to particular milestones. Instead, as we keep getting ready for, launching, and really carrying out this COVID-19 phase 2b trial, we'll have our costs covered and receive a fee.

Ed Berg

executive
#13

Thanks, Phil. The questions that came in about the Norovirus program are basically the same as what the analysts asked. So we're going to set that aside right now and move on to other questions. There's one regarding RSV. RSV is no longer part of your development pipeline. Could you please explain that decision further? And I think that Steve, if I could ask you to respond

Steven Lo

executive
#14

Right, so we constantly evaluate the pool of possible candidates to figure out where the strongest strategic openings lie, and any calls we make will hinge on a range of considerations — things like market conditions and competitive landscape, what resources we have, and timing. At this point, we're putting our energy into the opportunities that matter most, the ones that can push our science forward and produce data in the near term. Take our COVID-19 program, for instance — we're giving it a great deal of attention, and the fact that our agreements with BARDA could bring in as much as $453 million in funding is definitely a reason we'd move covid up the priority list.

Ed Berg

executive
#15

Appreciate that, Steve — I’ve got one more for you. Over the last five months, how has what you’ve seen at Vaxart lined up with what made you decide to come aboard in March?

Steven Lo

executive
#16

Yeah, so it's great to be part of this. Like I mentioned in a few of my remarks, the chances we've got to push our science forward really stand out to me, and honestly, during the first half of 2024 we've already managed to hit a few near term objectives. That includes the deal we signed with BARDA, plus there are possibilities ahead as we keep collaborating with the FDA on norovirus. And right now, what we intend to do is keep delivering through the second half of the year, which makes this an exciting yet crucial stretch for the business.

Edward Berg

analyst
#17

Appreciate it. I've got something for Dr. Tucker — given everything we've been hearing regarding avian flu, do you intend to move that program forward, and do you plan on, or are you looking to, obtain funding so that kind of advancement can happen?

Sean Tucker

executive
#18

Hello, yes, without a doubt, we are engaged in efforts to enhance every one of our vaccine constructs and are conducting preclinical testing on them. And when it comes to securing funding for these vaccine class candidates, including avian influenza, I should say we will be opportunistic — or optimistic.

Edward Berg

analyst
#19

Thanks. This is my final question, and it's directed at Steve. In what way do you think Vaxart's platform aligns with what the government envisions regarding vaccines of the next generation and getting ready for pandemics?

Steven Lo

executive
#20

Sure — so we've consistently held the view that our oral tablet and mucosal delivery platform will really set us apart from the COVID-19 vaccines that are already on the market. And I believe that's clear from the Project NextGen award we received, which lets us move ahead with this COVID-19 trial. So of course we're quite hopeful, and I think provided we keep delivering and keep pushing this trial forward, you know, it'll be hugely transformative for the company. So again, I think we feel very much on the same page as the government regarding what they're aiming to achieve. And you know, we're thrilled to be moving ahead.

Ed Berg

executive
#21

Great. Okay, I'd like to turn the call back over the operator.

Analyst

analyst
#22

This is Ali calling in for Mayank Mamtani. Thank you for fielding our question, and congratulations on the progress. I had a couple of quick questions. Is there any reason to think that your norovirus vaccine holds up better against newly emerging norovirus strains? Also, I was curious whether you might share your thoughts on the recent Phase 2b trial failure at HilleVax. And how do you see your position within the norovirus landscape? Thank you.

Steven Lo

executive
#23

Great. Well, thank you once more for that question. And yes, we have spent considerable time thinking about what took place with HillVax. What I'll do is hand things over to Sean so he can offer some comments there.

Sean Tucker

executive
#24

Absolutely. So once more, our view is that the HillVax results — with their vaccine candidate generating a robust serum response — really drive home what we've been saying: creating a mucosal response could be essential for an effective norovirus vaccine. Keep in mind that shots generally don't produce that kind of response. What we have so far shows our candidates deliver both a serum and a mucosal response, and we think that positions us to do considerably better. Another thing to remember is that our program currently targets healthy adults rather than infants, which makes comparing the two programs perhaps somewhat less meaningful. On your other question about cross reactivity, I'd say this: one important aspect of having an IGA response is that we've demonstrated — and others have too — that these can be far more cross reactive. That, in our view, gives it greater potential to handle what takes place when new strains or new outbreaks emerge.

Operator

operator
#25

Great. Thanks, everyone, that brings today’s teleconference to an end. We appreciate your taking part. At this point, you’re welcome to hang up, and have a wonderful day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Vaxart, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Vaxart, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Vaxart, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.